Follow
Sonya Heltshe
Sonya Heltshe
University of Washington School of Medicine
Verified email at seattlechildrens.org
Title
Cited by
Cited by
Year
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis
SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ...
American journal of respiratory and critical care medicine 190 (2), 175-184, 2014
4012014
SpiroSmart: using a microphone to measure lung function on a mobile phone
EC Larson, M Goel, G Boriello, S Heltshe, M Rosenfeld, SN Patel
Proceedings of the 2012 ACM Conference on ubiquitous computing, 280-289, 2012
2352012
Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections
KB Hisert, SL Heltshe, C Pope, P Jorth, X Wu, RM Edwards, M Radey, ...
American journal of respiratory and critical care medicine 195 (12), 1617-1628, 2017
2142017
Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections
KB Hisert, SL Heltshe, C Pope, P Jorth, X Wu, RM Edwards, M Radey, ...
American journal of respiratory and critical care medicine 195 (12), 1617-1628, 2017
1952017
Late diagnosis defines a unique population of long-term survivors of cystic fibrosis
DM Rodman, JM Polis, SL Heltshe, MK Sontag, C Chacon, RV Rodman, ...
American journal of respiratory and critical care medicine 171 (6), 621-626, 2005
1732005
Risk of total and aggressive prostate cancer and pesticide use in the Agricultural Health Study
S Koutros, LE Beane Freeman, JH Lubin, SL Heltshe, G Andreotti, ...
American journal of epidemiology 177 (1), 59-74, 2013
1702013
Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor
SL Heltshe, N Mayer-Hamblett, JL Burns, U Khan, A Baines, BW Ramsey, ...
Clinical Infectious Diseases 60 (5), 703-712, 2015
1542015
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data
FJ Accurso, F Van Goor, J Zha, AJ Stone, Q Dong, CL Ordonez, SM Rowe, ...
Journal of Cystic Fibrosis 13 (2), 139-147, 2014
1182014
Multiple-breath washout as a lung function test in cystic fibrosis. A cystic fibrosis foundation workshop report
P Subbarao, C Milla, P Aurora, JC Davies, SD Davis, GL Hall, S Heltshe, ...
Annals of the American Thoracic Society 12 (6), 932-939, 2015
1152015
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic …
MW Konstan, G Döring, SL Heltshe, LC Lands, KA Hilliard, P Koker, ...
Journal of Cystic Fibrosis 13 (2), 148-155, 2014
1122014
Occupational exposure to pesticides and bladder cancer risk
S Koutros, DT Silverman, MCR Alavanja, G Andreotti, CC Lerro, S Heltshe, ...
International journal of epidemiology 45 (3), 792-805, 2016
1082016
GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator …
SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ...
Am J Respir Crit Care Med 190 (2), 175-84, 2014
872014
Functional and psychosocial outcomes of older adults after burn injury: results from a multicenter database of severe burn injury
MB Klein, DC Lezotte, S Heltshe, J Fauerbach, RK Holavanahalli, ...
Journal of Burn Care & Research 32 (1), 66-78, 2011
832011
Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher
R Szczesniak, SL Heltshe, S Stanojevic, N Mayer-Hamblett
Journal of Cystic Fibrosis 16 (3), 318-326, 2017
802017
Heterogeneity in survival in adult patients with cystic fibrosis with FEV1< 30% of predicted in the United States
KJ Ramos, BS Quon, SL Heltshe, N Mayer-Hamblett, ED Lease, ...
Chest 151 (6), 1320-1328, 2017
752017
Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis
O Manor, R Levy, CE Pope, HS Hayden, MJ Brittnacher, R Carr, ...
Scientific reports 6 (1), 1-9, 2016
742016
Escherichia coli Dysbiosis Correlates With Gastrointestinal Dysfunction in Children With Cystic Fibrosis
LR Hoffman, CE Pope, HS Hayden, S Heltshe, R Levy, S McNamara, ...
Clinical infectious diseases 58 (3), 396-399, 2014
712014
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis
SL Heltshe, CH Goss, V Thompson, SD Sagel, DB Sanders, BC Marshall, ...
Thorax 71 (3), 223-229, 2016
672016
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations
NE West, VV Beckett, R Jain, DB Sanders, JA Nick, SL Heltshe, ...
Journal of Cystic Fibrosis 16 (5), 600-606, 2017
652017
Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation
D Gelfond, S Heltshe, C Ma, SM Rowe, C Frederick, A Uluer, L Sicilian, ...
Clinical and translational gastroenterology 8 (3), e81, 2017
642017
The system can't perform the operation now. Try again later.
Articles 1–20